CYTO
Altamira Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · BM
$0.30
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +127.8%
- EBIT
- +75.5%
- EPS
- -15.7%
- Free cash flow
- +13.2%
- Operating cash flow
- +24.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +92.3%
- EBIT
- +67.2%
- Net income
- +72.6%
- EPS
- +97.5%
- Free cash flow
- -6.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2023